The technology was developed at the University of Bristol by professor Varinder Aggarwal and colleagues.
It is said to simplify the synthesis of prostaglandins, improve manufacturing efficiency by 5-10 fold and substantially reduce manufacturing costs.
Topokine Therapeutics president and CEO Murat Kalayoglu said, "This exclusive license further enhances our IP position, and we are excited to collaborate with him and the University of Bristol."
Topokine’s lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat.
XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis, claims the company.